(Q49020806)

17 February 2018

title

Guidelines for the automated evaluation of Elispot assays. (English)

1 reference

17 February 2018

1 reference

Sylvia Janetzki

1

1 reference

17 February 2018

Leah Price

2

1 reference

17 February 2018

Helene Schroeder

3

1 reference

17 February 2018

Cedrik M Britten

4

1 reference

17 February 2018

Marij J P Welters

5

1 reference

17 February 2018

Axel Hoos

6

1 reference

17 February 2018

publication date

25 June 2015

1 reference

17 February 2018

published in

Nature Protocols

1 reference

17 February 2018

volume

10

1 reference

17 February 2018

issue

7

1 reference

17 February 2018

page(s)

1098-1115

1 reference

17 February 2018

https://scigraph.springernature.com/pub.10.1038/nprot.2015.068

exact match

0 references

cites work

A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2015.068

The role of IFN-gamma Elispot assay in HIV vaccine research

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2015.068

Enzyme-linked immunospot assays for direct ex vivo measurement of vaccine-induced human humoral immune responses in blood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2015.068

Sensitivity of a new commercial enzyme-linked immunospot assay (T SPOT-TB) for diagnosis of tuberculosis in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2015.068

Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2015.068

Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2015.068

Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2015.068

Triple Cytokine FluoroSpot Analysis of Human Antigen-Specific IFN-γ, IL-17A and IL-22 Responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2015.068

A Fluorospot assay to detect single T lymphocytes simultaneously producing multiple cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2015.068

Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2015.068

Harmonization of immune biomarker assays for clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2015.068

How ELISPOT morphology reflects on the productivity and kinetics of cells' secretory activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2015.068

Improvement of IFNg ELISPOT Performance Following Overnight Resting of Frozen PBMC Samples Confirmed Through Rigorous Statistical Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2015.068

Results of an ELISPOT proficiency panel conducted in 11 laboratories participating in international human immunodeficiency virus type 1 vaccine trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2015.068

Identification of major factors influencing ELISpot-based monitoring of cellular responses to antigens from Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2015.068

Response definition criteria for ELISPOT assays revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2015.068

Single-cell technologies for monitoring immune systems.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2015.068

Linking T-cell receptor sequence to functional phenotype at the single-cell level

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2015.068

A harmonized approach to intracellular cytokine staining gating: Results from an international multiconsortia proficiency panel conducted by the Cancer Immunotherapy Consortium (CIC/CRI)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2015.068

Stepping up ELISpot: Multi-Level Analysis in FluoroSpot Assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2015.068

The effect of apoptotic cells on virus-specific immune responses detected using IFN-gamma ELISPOT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2015.068

Isolation and preservation of peripheral blood mononuclear cells for analysis of islet antigen-reactive T cell responses: position statement of the T-Cell Workshop Committee of the Immunology of Diabetes Society

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2015.068

Overnight resting of PBMC changes functional signatures of antigen specific T- cell responses: impact for immune monitoring within clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2015.068

Harmonisation of short-term in vitro culture for the expansion of antigen-specific CD8(+) T cells with detection by ELISPOT and HLA-multimer staining

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2015.068

Optimization of a human IgG B-cell ELISpot assay for the analysis of vaccine-induced B-cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2015.068

The Granzyme B ELISPOT assay: an alternative to the 51Cr-release assay for monitoring cell-mediated cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2015.068

Granulocyte contamination dramatically inhibits spot formation in AIDS virus-specific ELISpot assays: analysis and strategies to ameliorate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2015.068

Quantification of CD8+ T lymphocytes responsive to human immunodeficiency virus (HIV) peptide antigens in HIV-infected patients and seronegative persons at high risk for recent HIV exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2015.068

Harmonization of the intracellular cytokine staining assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2015.068

Drug development: Raise standards for preclinical cancer research

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2015.068

Use of overlapping peptide mixtures as antigens for cytokine flow cytometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2015.068

Performance of serum-supplemented and serum-free media in IFNgamma Elispot Assays for human T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2015.068

HPC viability measurement: trypan blue versus acridine orange and propidium iodide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2015.068

Overview of membranes and membrane plates used in research and diagnostic ELISPOT assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2015.068

Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2015.068

Reverse ELISPOT assay for clonal analysis of cytokine production I. Enumeration of gamma-interferon-secreting cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2015.068

T Cell Assays and MIATA: The Essential Minimum for Maximum Impact

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2015.068

The impact of harmonization on ELISPOT assay performance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2015.068

Evaluation of Elispot assays: influence of method and operator on variability of results

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2015.068

Intracellular cytokine optimization and standard operating procedure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2015.068

Quality assurance for polychromatic flow cytometry

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2015.068

Enzyme-Linked ImmunoSpot (ELISpot) for Single-Cell Analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2015.068

Detection of HIV vaccine-induced cell-mediated immunity in HIV-seronegative clinical trial participants using an optimized and validated enzyme-linked immunospot assay

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2015.068

Response determination criteria for ELISPOT: toward a standard that can be applied across laboratories

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2015.068

A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2015.068

31 March 2020

Identifiers

DOI

10.1038/NPROT.2015.068

1 reference

17 February 2018

Dimensions Publication ID

0 references

1 reference

17 February 2018